Lonza launched its AI-enabled Route Scouting Service offering which is designed to streamline synthetic route identification for novel APIs by combining Lonza’s global chemical supply chain intelligence and in-house expertise with AI technology from Elsevier (Reaxys).

Lonza推出了其人工智能路线侦察服务，旨在通过将Lonza的全球化学供应链智能和内部专业知识与Elsevier（Reaxys）的人工智能技术相结合，简化新型API的合成路线识别。

The complexity of small molecule APIs entering the development pipeline is steadily increasing, and the intricate structures of modern drug candidates are driving an increase in the number of synthetic steps required to produce them, according to Simon Wagschal, PhD, associate director, advanced chemistry technologies, small molecules R&D, Lonza..

Lonza小分子研发高级化学技术副总监Simon Wagschal博士表示，进入开发流程的小分子原料药的复杂性正在稳步增加，现代候选药物的复杂结构正在推动生产它们所需的合成步骤数量的增加。。

More synthetic steps can result in longer lead times and a need to manage more raw materials. These factors increase the time and cost of developing an effective synthesis and potentially extend the time to clinical trial readiness.

更多的合成步骤可能会导致更长的交付周期，并且需要管理更多的原材料。这些因素增加了开发有效合成的时间和成本，并可能延长临床试验准备时间。

The new Route Scouting Service offering combines Lonza’s process R&D expertise and supply chain databases with AI-enabled computer-aided synthesis planning technology (CSPT). With access to global chemical supply chain intel and the predictive power of AI, the new offering provides synthetic pathways that are more supply chain resilient and offer insights for optimal route design on both clinical and commercial manufacturing, continued Wagschal, who noted that the integrated service can provide intellectual property, reduce COGS, and improve supply chain security for customers..

新的路线侦察服务将Lonza的工艺研发专业知识和供应链数据库与支持人工智能的计算机辅助综合规划技术（CSPT）相结合。Wagschal继续说道，凭借全球化学供应链intel和人工智能的预测能力，新产品提供了更具供应链弹性的合成途径，并为临床和商业制造的最佳路线设计提供了见解，他指出，集成服务可以为客户提供知识产权，减少COG，提高供应链安全性。。

“Robust retrosynthesis is key in creating efficient, scalable syntheses for novel drug candidates, he explained. “Today, researchers benefit from using CSPTs with analytical search and powerful predictive capabilities.

他解释说：“强大的逆转录合成是为新型候选药物创建高效，可扩展合成的关键。”今天，研究人员受益于使用具有分析搜索和强大预测能力的CSPT。

“By integrating our unique supply chain insights and predictions reflecting Lonza’s decades of experience and knowledge of clinical and commercial manufacturing, global sourcing of raw materials and intermediates, our new Route Scouting Service helps chemistry, manufacturing and control teams overcome the challenge of rising API complexity.”.

“通过整合我们独特的供应链见解和预测，反映了Lonza在临床和商业制造、全球原材料和中间体采购方面数十年的经验和知识，我们的新路线侦察服务可帮助化学、制造和控制团队克服API复杂性不断上升的挑战。”。

NewsArtificial intelligenceClinical trialSmall moleculesElsevierLonza

新闻人工智能临床试验小分子ElsevierLonza